Clinical Study
Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer
Table 1
Levels of tumour-infiltrating lymphocytes (TILs) in women with LLABCs(1) and subsequent pathological complete response following NAC(2).
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
LLABCs: large and locally advanced breast cancers; (2)NAC: neoadjuvant chemotherapy; (3)PCR (grade 5): no residual invasive disease; (4)LPBC: lymphocyte-predominant breast cancer; statistically significant. |